ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

UICC Names Banker As Chief Executive

September 11, 2009

Hilton Head, SC, Physician’s Files Subpoenaed By FBI

March 18, 1994

Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk

April 29, 2011

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

Bioethics Commission Report Calls For funding To Derive Stem Cells

September 17, 1999